Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibition has been shown to successfully reactivate T cell responses directed against tumor‑associated antigens, resulting in significantly prolonged overall survival in patients with various types of solid tumors. Among them, cytotoxic T‑lymphocyte protein 4 (CTLA‑4) and programmed cell death protein 1 (PD‑1) play key roles in tumor immune escape and are well‑established targets of cancer immunotherapy. However, the low response rate PD‑1 and CTLA‑4 is a limitation and a challenge. Hence, studies have focused on investigating the tumor microenvironment for alternative therapeutic targets. Lymphocyte activation gene 3 protein (LAG‑3) negatively regulates T lymphocytes by binding to the extracellular domain of the ligand, thus avoiding autoimmunity caused by T cell overactivation. LAG‑3 is an important immune checkpoint in vivo and plays a balanced regulatory role in the human immune system. LAG‑3 is now regarded as a new generation of immunotherapy targets. The present review describes the research progress of LAG‑3 to provide reference for further investigation of LAG‑3. The immune checkpoint of LAG‑3 plays a crucial role in cancer development and may be used in future clinical practice of cancer therapy.
No takes yet. Share an insight, caveat, or question.
Shan et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: